Why Is Cronos Group (TSX:CRON) Delaying Its Earnings Results?

This could be the reason why investors in cannabis firm Cronos Group’s stock learned of an earnings release delay on Monday.

| More on:
question marks written reminders tickets

Image source: Getty Images

Cannabis producer and innovation giant Cronos Group (TSX:CRON)(NASDAQ:CRON) announced on Monday that it will delay the release of its fourth quarter and full year 2019 earnings results originally slated for Thursday, February 27 as it has experienced a delay.

No reason was given for the earnings release postponement, no new specific date was given for the delayed filings and the company will come back to the market with a new date in a news release.

The delay could be excusable, however.

What do we know?

The company says it has experienced a delay in the completion of its financial statements.

The expected results are the company’s first set after announcing a change in its dormitory and primary listing from Canada to the United States.

As highlighted earlier, the company is now primarily a United States based dual-listed firm, meaning that it is mandated to report its upcoming reports under the United States Generally Accepted Accounting Principles (U.S. GAAP) and not under International Financial Reporting Standards (IFRS), as was the case since its inception in Canada.

Now, changing the set of reporting standards may not be an easy walk in the park.

US GAAP and IFRS’s thick volumes differ substantially in that IFRS are principles based, giving some room for some flexibility and discretion while US GAAP is strictly rules based.

Rules need strict interpretation just in case you unintentionally break them. A great deal of time goes into such interpretations, especially when one is changing from a relatively more flexible set of financial reporting guidelines to a generally rigid thick set of accounting rules.

Although the respective accounting standards setting boards (the Financial Accounting Standards Board (FASB) for U.S. GAAP and the International Accounting Standards Board (IASB) for IFRS) have been tirelessly working on a convergence path for accounting and reporting standards for several years with the recent IFRS 15 introduction being one product of such efforts, some significant differences in the treatment of specific accounting items remains.

While US GAAP may be slowly adopting IFRS flexibility, differences still persist in allowable inventory accounting methods, fair value reporting and adjustments for inventories, fixed assets and intangibles as well as reversals of impairment losses, while fixed assets accounting, leases and intangible assets accounting treatments still need alignment.

Cronos is a recently transformed international operator

The U.S. GAAP framework only applies to the U.S.-based firms, while most other countries have adopted the IFRS (over 110 countries globally) or have their own financial reporting standards that could be largely similar to IFRS.

International companies based in the United States have a tougher time complying with US GAAP reporting as their subsidiaries are required to file statements under a different set of recording and reporting principles.

Before the recent acquisition of a U.S. hemp subsidiary, Cronos had its major business operations (five subsidiaries) in Canada and four subsidiaries in Israel, another in Malta and one more subsidiary based in Ireland.

All these businesses use IFRS for internal reporting, and accountants have to consolidate their results under a new set of rules for the very first time while also integrating the new major American segment into the fold.

Foolish bottom line

The company had a huge task in trying to switch to US GAAP reporting in a few months while consolidating a major acquisition, and facing delays could be an understandable excuse for postponing the release of its very first set of financial results under its new home country’s reporting rules.

That said, the company could still have faced a different set of challenges altogether, and this we may never know.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any stocks mentioned.  

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Are Cannabis Stocks a Good Buy in March 2023?

Cannabis stocks like Canopy Growth Corp (TSX:WEED) are still being talked about, but are they worth buying?

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Down 26% in a Month, Is Canopy a Buy Today?

Canopy Growth Corp (TSX:WEED) is down 26% in a month. Is it time to start bottom fishing?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

What’s Next for Aurora Cannabis Stock?

Aurora Cannabis stock is down 99% from all-time highs. Is ACB stock a buy, sell, or hold in March 2023?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock: Undervalued Gem or Falling Knife?

Canopy Growth remains a high-risk bet, despite falling 95% from all-time highs. Let's see why you need to avoid WEED…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

3 Things to Know About Canopy Growth Stock After Earnings

A new focus on profitability and sustainability might stop the cash burn at Canopy Growth, so the stock can see…

Read more »

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »